• May 30, 2021
alidea

Abirateron u metastazujícího karcinomu prostaty

Abirateron u metastazujícího karcinomu prostaty bez předchozí chemoterapie. Abiraterone acetate, an androgen biosynthesis inhibitor, improves total survival in sufferers with metastatic castration-resistant prostate most cancers after chemotherapy. We evaluated this agent in sufferers who had not acquired earlier chemotherapy. METHODS On this double-blind examine, we randomly assigned 1088 sufferers to obtain abiraterone acetate (1000 mg)…

Read More